An evaluation of selexipag for the treatment of pulmonary hypertension

References

• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37:67–119.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801913.
   PubMed Web of Science ®Google Scholar
• Swinnen K, Quarck R, Godinas L, et al. Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. Eur Respir Rev. 2019 Dec;28:154.
   Web of Science ®Google Scholar
• Kawut S, Taichman D, Archer-Chicko C, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;123(2):344–350.
   PubMed Web of Science ®Google Scholar
• D’Alonzo G, Barst R, Ayres S, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–1030.
   PubMed Web of Science ®Google Scholar
• McGoon M, Benza R, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25 Supplement):D51–D59.
   PubMed Web of Science ®Google Scholar
• Benza R, Miller D, Barst R, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142(2):448–456.
   PubMed Web of Science ®Google Scholar
• Gaine S, Rubin L. Primary pulmonary hypertension. Lancet. 1998;352(9129):719–725.
   PubMed Web of Science ®Google Scholar
• Barst R, Rubin L, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301.
   PubMed Web of Science ®Google Scholar
• Picken C, Fragkos K, Eddama M, et al. Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: a systematic review and meta-analysis. J Clin Med. 2019;8(4):pii:E481.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Hoeper M, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40:874–880.
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53(1):1801916.
   PubMed Web of Science ®Google Scholar
• Hansmann G, Meinel K, Bukova M, et al. European pediatric pulmonary vascular disease network (EPPVDN). Selexipag for the treatment of children with pulmonary arterial hypertension: first multicenter experience in drug safety and efficacy. J Heart Lung Transplant. 2020;7:S1053-2498(20)31490-X.
   Google Scholar
• Geerdink LM, Bertram H, Hansmann G. First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. Pulm Circ. 2017;7:551–554.
   PubMed Web of Science ®Google Scholar
• Gallotti R, Drogalis-Kim DE, Satou G, et al. Single-center experience using selexipag in a pediatric population. Pediatr Cardiol. 2017;38:1405–1409.
   PubMed Web of Science ®Google Scholar
• A study of selexipag as add-on treatment to standard of care in children with pulmonary arterial hypertension. [cited 2020 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/nct04175600
   Google Scholar
• A study to find out if selexipag is effective and safe in patients with chronic thromboembolic pulmonary hypertension when the disease is inoperable or persistent/recurrent after surgery and/or international treatment (SELECT). [cited 2020 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03689244
   Google Scholar
• Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev. 2015;24(138):621–629.
   PubMed Web of Science ®Google Scholar
• Barst R, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119–2125.
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 322(3): 1181–1188. 2007.
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5, 6-diphenyl pyridin-2-yl)(isopropyl) amino] butoxy}-N-(methylsulfonyl) acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form,{4-[(5, 6-diphenyl pyridin- 2-yl)(isopropyl) amino] butoxy} acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther. 2008;326:691–699.
   PubMed Web of Science ®Google Scholar
• Asaki T, Kuwano K, Morrison K, et al. Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem. 2015;58(18):7128–7137.
   PubMed Web of Science ®Google Scholar
• Jing Z, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127:624–633.
   PubMed Web of Science ®Google Scholar
• White R, Jerjes-Sanchez C, Bohns Meyer G, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707‐717.
   Web of Science ®Google Scholar
• Adams J, Morgan M, Unett D, et al. Pharmacokinetics and pre-clinical efficacy of ralinepag (APD811) in humans and rats. Eur Respir J. 2017;50:OA4662.
   Web of Science ®Google Scholar
• Torres F, Farber H, Ristic A, et al. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019;54(4).
   Web of Science ®Google Scholar
• Klinger J, Elliott G, Levine D, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565–586.
   PubMed Web of Science ®Google Scholar
• Gatfield J, Menyhart K, Nayler O. Anti-contractile and antiproliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist [abstract no. P2353]. Eur Respir J. 2014;44(Suppl58). DOI:https://doi.org/10.1183/09031936.00003814
   Google Scholar
• Gatfield J, Menyhart K, Tunis M, et al. Selectivity of the selexipag active metabolite ACT-333679 for the IP receptor avoids DP1 or EP2-mediated inhibition of natural killer cell responses in vitro [abstract no. 2238 plus poster]. Am J Respir Crit Care Med. 2016;193:A2238.
   Web of Science ®Google Scholar
• Morrison K, Wanner D, Gatfield J, et al. Repeated oral administration of the selective prostacyclin receptor agonist selexipag does not cause tachyphylaxis in spontaneously hypertensive rats [abstract 1214-172]. J Am Coll Cardiol. 2015;65(suppl):A1558.
   Google Scholar
• Uptravi [package insert and label information]. [cited 2020 Jun 1]. Available from: https://uptravi.com/pdf/UPTRAVI-Full-Prescribing-Information.pdf
   Google Scholar
• Janssen-Cilag Ltd. Summary of product characteristics - selexipag; [updated 2020 Feb 19; cited 2020 Jun 1]. Available from: https://www.medicines.org.uk/emc/product/2163/smpc
   Google Scholar
• Bruderer S, Hurst N, Kaufmann P, et al. Multiple dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology. 2014;94:145–156.
   Web of Science ®Google Scholar
• Kaufmann P, Hurst N, Astruc B, et al. Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. Eur J Clin Pharmacol. 2017 Feb;73(2):151–156.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Okubo K, Bruderer S, et al. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 2015;15(3):195–203.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Okubo K, Sidharta PN, et al. Investigation of the absorption, metabolism, and excretion of 14C-selexipag following oral administration to healthy male subjects. Clin Pharmacol Ther. 2012;92(supplement S1):S85.
   Google Scholar
• Baldoni D, Bruderer S, Muhsen N, et al. Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study. Int J Clin Pharmacol Ther. 2015 Sep;53(9):788–798.
   PubMed Web of Science ®Google Scholar
• Boehler M, Bruderer S, Ulč I, et al. Biocomparison study of adult and paediatric dose strengths of the prostacyclin receptor agonist selexipag. Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):115–120.
   PubMed Web of Science ®Google Scholar
• Hoch M, Darpo B, Remenova T, et al. A thorough QT study in the context of an uptitration regiment with selexipag, a selective oral prostacyclin receptor agonist. Drug Des Devel Ther. 2015;9:175–185.
   PubMed Web of Science ®Google Scholar
• A clinical study to assess the effect of clopidogrel on the pharmacokinetics of selexipag and its active metabolite in healthy male subjects. cited 2020 Jun 1. Available from: https://clinicaltrials.gov/ct2/show/NCT03496506
   Google Scholar
• Bruderer S, Petersen-Sylla M, Boehler M, et al. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. Br J Clin Pharmacol. 2017 Dec;83(12):2778–2788.
   PubMed Web of Science ®Google Scholar
• Denton CP, Hachulla É, Riemekasten G, et al. Efficacy and safety of selexipag in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol. 2017 Dec;69(12):2370–2379.
   PubMed Web of Science ®Google Scholar
• A clinical study of to confirm the doses of selexipag in children with pulmonary arterial hypertension. cited 2020 Jun 1. Available from: https://clinicaltrials.gov/ct2/show/NCT03492177
   Google Scholar
• A study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag. cited 2020 Jun 1. Available from: https://clinicaltrials.gov/ct2/show/NCT03942211
   Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533.
   PubMed Web of Science ®Google Scholar
• Lang I, Gaine S, Galie N, et al. Effect of selexipag on long-term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: results from the GRIPHON study [abstract 2365]. Eur Heart J. 2015;36(suppl 1):381–382.
   Google Scholar
• Klose H, Chin K, Ewert R, et al. Safety, tolerability and pharmacokinetics study in patients with pulmonary arterial hypertension (PAH) temporarily switching from oral to IV selexipag. J Heart Lung Transplant. 2019;38(4):S490.
   Web of Science ®Google Scholar
• ACT-293987 in Pulmonary Arterial Hypertension. cited 2020 Jun 1. Available from: https://clinicaltrials.gov/ct2/show/NCT01112306
   Google Scholar
• Frost A, Janmohamed M, Fritz J, et al. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: results from the TRANSIT-1 study. J Heart Lung Transplant. 2019;38(1):43–50.
   PubMed Web of Science ®Google Scholar
• Chin K, Sitbon O, Doelberg M, et al. Efficacy and safety of initial triple oral versus initial double oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (PAH): results of the randomized controlled TRITON study. Am J Respir Crit Care Med. 2020;201:A2928.
   Google Scholar
• Effect of selexipag on daily life physical activity of patients with pulmonary arterial hypertension (TRACE). cited 2020 Jun 1. Available from: https://clinicaltrials.gov/ct2/show/NCT03078907
   Google Scholar
• Koestenberger M, Hansmann G. Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension? Pulm Circ. 2018;8(3):2045894018793580.
   Web of Science ®Google Scholar
• Mullard A. 2015 FDA drug approvals. Nat Rev Drug Discov. 2016;15:73–76.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Chin M, Channick N, et al. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J Heart Lung Transplant. 2020;39(4):300–309.
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Channick R, De Marco T, et al. Results of an expert consensus survey on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents. Chest. 2020;157(4):955–965.
   PubMed Web of Science ®Google Scholar
• Barnikel M, Kneidinger N, Klenner F, et al. Real-life data on selexipag for the treatment of pulmonary hypertension. Pulm Circ. 2019;9(1):2045894019832199.
   Web of Science ®Google Scholar
• Yanaka K, Guillien A, Soumagne T, et al. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution. Eur Respir J. 2020;55(6):1902418.
   Google Scholar
• Fanous S, Janmohamed M. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: case series. Am J Health Syst Pharm. 2018;75(23):1877–1881.
   PubMed Web of Science ®Google Scholar
• Holthaus N, Prins K, Rose L, et al. EXPRESS: transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients. Pulm Circ. 2019;9(3):2045894019862167.
   Web of Science ®Google Scholar
• Barnes H, Yeoh H, Fothergillb T, et al. Prostacyclin for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2019;5.
   Web of Science ®Google Scholar